Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - capsaicin - cutaneous cream - 750microgram/1gram

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported - capsaicin - cutaneous cream - 250microgram/1gram

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported - capsaicin - cutaneous cream - 750microgram/1gram

USA - engelsk - NLM (National Library of Medicine)

wal-mart stores inc - capsaicin (unii: s07o44r1zm) (capsaicin - unii:s07o44r1zm) - capsaicin - topical analgesic temporarily relieves minor aches and pains of muscles and joints due to - simple backache - arthritis - strains - sprains

USA - engelsk - NLM (National Library of Medicine)

tmig, inc. - capsaicin (unii: s07o44r1zm) (capsaicin - unii:s07o44r1zm) - capsaicin 0.025 g in 100 g - capsaicin cream 0.025% ranitidine tablet usp 150mg diclofenac sodium tablet 75mg

Israel - engelsk - Ministry of Health

rafa laboratories ltd - capsaicin - cream - capsaicin 0.025 % - capsaicin - capsaicin - for the symptomatic relief of pain associated with arthritis.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - capsaicin, quantity: 0.075 % w/w - cream - excipient ingredients: purified water; cetyl alcohol; isopropyl myristate; benzyl alcohol; sorbitol solution (70 per cent) (non-crystallising); white soft paraffin; glyceryl monostearate; peg-100 stearate - 1. for the symptomatic relief of neuralgia following herpes zoster infections (post-herpetic neuralgia) after open skin lesions have healed.,2. for the symptomatic management of medically diagnosed painful diabetic peripheral polyneuropathy.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - capsaicin, quantity: 0.025 % w/w - cream - excipient ingredients: cetyl alcohol; white soft paraffin; sorbitol solution (70 per cent) (non-crystallising); purified water; benzyl alcohol; isopropyl myristate; glyceryl monostearate; peg-100 stearate - for the symptomatic relief of pain associated with osteoarthritis.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

first pharma pty ltd - capsaicin, quantity: 0.25 mg/g - cream - excipient ingredients: benzyl alcohol; sorbitol solution (70 per cent) (crystallising); isopropyl myristate; white soft paraffin; cetyl alcohol; purified water; glyceryl monostearate; peg-100 stearate - may be useful as an adjunct in the temporary relief of pain associated with arthritis. may be useful for the treatment of post-herpetic neuralgia (pain following shingles)

USA - engelsk - NLM (National Library of Medicine)

averitas pharma inc - capsaicin (unii: s07o44r1zm) (capsaicin - unii:s07o44r1zm) - qutenza is indicated in adults for the treatment of neuropathic pain associated with postherpetic neuralgia (phn) and for neuropathic pain associated with diabetic peripheral neuropathy (dpn) of the feet. none. risk summary capsaicin is negligibly absorbed systemically following topical administration of qutenza, and maternal use is not expected to result in the fetal exposure to qutenza. in animal reproductive studies, no evidence of malformations were observed when capsaicin was administered daily by the topical route to pregnant rats and rabbits during the period of organogenesis at doses of up to 11- and 37-times, respectively, the maximum recommended human dose (mrhd) of qutenza at 716 mg capsaicin per day (4 topical systems containing 179 mg/topical systems). in a peri- and postnatal development study, no adverse effects were observed when capsaicin was administered daily by the topical route to rats during implantation to weaning at doses of up to 11-times the mrhd (see data) . the estimated backgro